drugset / Trial / NCT05698043

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

NCT05698043

Phase 1 Completed 63 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)

Timeline

Start
2023-07-17
Primary completion
2023-09-01
Completion
2023-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-386(5) Unknown Oral
Subject D013 Unknown Oral
Subject D326 Unknown Oral
Subject D337 Unknown Oral